Novolog Pharm-Up 1966 Ltd (NVLG) - Total Assets
Based on the latest financial reports, Novolog Pharm-Up 1966 Ltd (NVLG) holds total assets worth ILA2.15 Billion ILA (≈ $5.76 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See net assets of Novolog Pharm-Up 1966 Ltd for net asset value and shareholders' equity analysis.
Novolog Pharm-Up 1966 Ltd - Total Assets Trend (2014–2025)
This chart illustrates how Novolog Pharm-Up 1966 Ltd's total assets have evolved over time, based on quarterly financial data.
Novolog Pharm-Up 1966 Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Novolog Pharm-Up 1966 Ltd's total assets of ILA2.15 Billion consist of 67.8% current assets and 32.2% non-current assets.
| Asset Category | Amount (ILA) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 5.7% |
| Accounts Receivable | ILA1.07 Billion | 50.0% |
| Inventory | ILA250.78 Million | 11.7% |
| Property, Plant & Equipment | ILA0.00 | 0.0% |
| Intangible Assets | ILA179.40 Million | 8.4% |
| Goodwill | ILA145.04 Million | 6.8% |
Asset Composition Trend (2014–2025)
This chart illustrates how Novolog Pharm-Up 1966 Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Novolog Pharm-Up 1966 Ltd.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Novolog Pharm-Up 1966 Ltd's current assets represent 67.8% of total assets in 2025, a decrease from 95.1% in 2014.
- Cash Position: Cash and equivalents constituted 5.7% of total assets in 2025, down from 6.5% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 14.0% of total assets, an increase from 1.0% in 2014.
- Asset Diversification: The largest asset category is accounts receivable at 50.0% of total assets.
Novolog Pharm-Up 1966 Ltd Competitors by Total Assets
Key competitors of Novolog Pharm-Up 1966 Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
China National Medicines Corp Ltd
SHG:600511
|
China | CN¥35.13 Billion |
|
Liaoning Cheng Da Co Ltd
SHG:600739
|
China | CN¥50.48 Billion |
|
Paragon Care Limited
F:PXS
|
Germany | €1.75 Billion |
|
Sigma Healthcare Ltd
AU:SIG
|
Australia | AU$8.74 Billion |
|
Ebos Group Ltd
AU:EBO
|
Australia | AU$8.80 Billion |
|
Paragon Care Ltd
AU:PGC
|
Australia | AU$1.31 Billion |
|
Mayne Pharma Group Ltd
AU:MYX
|
Australia | AU$1.01 Billion |
|
Cyclopharm Ltd
AU:CYC
|
Australia | AU$46.10 Million |
Novolog Pharm-Up 1966 Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.91 | 0.96 | 1.04 |
| Quick Ratio | 0.75 | 0.83 | 0.91 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ILA-146.97 Million | ILA-93.45 Million | ILA65.64 Million |
Novolog Pharm-Up 1966 Ltd - Advanced Valuation Insights
This section examines the relationship between Novolog Pharm-Up 1966 Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.31 |
| Latest Market Cap to Assets Ratio | 0.05 |
| Asset Growth Rate (YoY) | -29.3% |
| Total Assets | ILA2.15 Billion |
| Market Capitalization | $117.79 Million USD |
Valuation Analysis
Below Book Valuation: The market values Novolog Pharm-Up 1966 Ltd's assets below their book value (0.05x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Novolog Pharm-Up 1966 Ltd's assets decreased by 29.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Novolog Pharm-Up 1966 Ltd (2014–2025)
The table below shows the annual total assets of Novolog Pharm-Up 1966 Ltd from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ILA2.15 Billion ≈ $5.76 Million |
-29.29% |
| 2024-12-31 | ILA3.04 Billion ≈ $8.14 Million |
+8.91% |
| 2023-12-31 | ILA2.79 Billion ≈ $7.48 Million |
+14.54% |
| 2022-12-31 | ILA2.43 Billion ≈ $6.53 Million |
+6.38% |
| 2021-12-31 | ILA2.29 Billion ≈ $6.14 Million |
+4.66% |
| 2020-12-31 | ILA2.19 Billion ≈ $5.86 Million |
+1.69% |
| 2019-12-31 | ILA2.15 Billion ≈ $5.76 Million |
+24.14% |
| 2018-12-31 | ILA1.73 Billion ≈ $4.64 Million |
-4.09% |
| 2017-12-31 | ILA1.81 Billion ≈ $4.84 Million |
+18.55% |
| 2016-12-31 | ILA1.52 Billion ≈ $4.08 Million |
-7.07% |
| 2015-12-31 | ILA1.64 Billion ≈ $4.39 Million |
+24.33% |
| 2014-12-31 | ILA1.32 Billion ≈ $3.53 Million |
-- |
About Novolog Pharm-Up 1966 Ltd
Novolog (Pharm-Up 1966) Ltd provides healthcare services in Israel. The company operates through three divisions: Logistics, Healthcare Services, and Digital. The Logistics division engages in the import and distribution of pharmaceuticals and medical products; logistics of clinical trials and related services; provision of pharmaceutical services to customers; and sterilization and validation pr… Read more